Canget BioTekpharma Overview
- Founded
-
2012
- Status
-
Private
- Employees
-
8
- Latest Deal Type
-
Accelerator/Inc
- Investors
-
2
Canget BioTekpharma General Information
Description
Operaator of a biotechnology company intended to develop novel, cancer-targeting anticancer agents. The company provides highly effective, low-toxic, and cancer-targeting anticancer agents for patients, enabling medical practitioners to dramatically improve patient survival time and survival rate through controlling cancer cell drug resistance and tumor relapse.
Contact Information
Website
www.canget-biotek.com
Ownership Status
Privately Held (backing)
Financing Status
Accelerator/Incubator Backed
Primary Industry
Biotechnology
Primary Office
- 701 Ellicott Street
- Buffalo, NY 14203
- United States
+1 (716) 000-0000
Canget BioTekpharma Timeline
Canget BioTekpharma Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 9. Accelerator/Incubator | 00000 | Completed | Startup | |||
| 8. Angel (individual) | 01-Jul-2021 | 00000 | Completed | Pre-Clinical Trials | ||
| 7. Angel (individual) | 29-Feb-2020 | 00000 | 00000 | Completed | Pre-Clinical Trials | |
| 6. Angel (individual) | 01-Feb-2020 | Cancelled | Pre-Clinical Trials | |||
| 5. Angel (individual) | 03-Jul-2019 | 00000 | 00000 | Completed | Pre-Clinical Trials | |
| 4. Grant | 14-Aug-2018 | 00000 | Completed | Startup | ||
| 3. Grant | 01-Jan-2018 | 00000 | Completed | Startup | ||
| 2. Grant | 01-Jan-2015 | $2.1M | Completed | Startup | ||
| 1. Grant | 01-Jan-2014 | $225K | Completed | Startup |
Canget BioTekpharma Patents
Canget BioTekpharma Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4003352-A1 | Novel anticancer drug fl118 formulation in combination with immunotherapy for treatment of human cancer | Pending | 22-Jul-2019 | 00000000000 | |
| US-20220249464-A1 | Novel anticancer drug fl118 formulation in combination with immunotherapy for treatment of human cancer | Pending | 22-Jul-2019 | 00000000000 | |
| AU-2020315841-A1 | Novel anticancer drug fl118 formulation in combination with immunotherapy for treatment of human cancer | Pending | 22-Jul-2019 | 00000000000 | |
| CA-3146165-A1 | Novel anticancer drug fl118 formulation in combination with immunotherapy for treatment of human cancer | Pending | 22-Jul-2019 | 00000000000 | |
| EP-3852760-A4 | Matter of composition, synthesis, formulation and application of fl118 platform positions 7 and 9-derived analogues for treatment of human disease | Pending | 17-Sep-2018 | A61K9/2054 | 0 |
Canget BioTekpharma Executive Team (5)
Canget BioTekpharma Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Canget BioTekpharma Investors (2)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| U.S. Department of Health and Human Services | Government | 000 0000 | 000000 0 | ||
| Start-up NY | Accelerator/Incubator | Minority | 000 0000 | 000000 0 |